STOCK TITAN

CNBX Pharmaceuticals Inc - CNBX STOCK NEWS

Welcome to our dedicated news page for CNBX Pharmaceuticals (Ticker: CNBX), a resource for investors and traders seeking the latest updates and insights on CNBX Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CNBX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CNBX Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.69%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
CNBX Pharmaceuticals Inc

OTC:CNBX

CNBX Rankings

CNBX Stock Data

463.56k
27.07M
10.67%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Bethesda

About CNBX

cannabics pharmaceuticals is dedicated to the development of advanced cannabinoid-based treatments and therapies. the company’s main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. these advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on cannabinoid compounds. cannabics' research is devoted to the discovery of cannabinoid compounds targeted to specific cancers based on cutting edge high through-output screening and bioinformatic tools. the company’s principal product is cannabics sr, a long acting oil capsule that provides a safe, effective and reliable administration of cannabis. composed solely from food grade materials, cannabics sr 25mg delivers a steady level of beneficial effects for 10–12 hours . the once-per day oral dosing regimen offered by cannabics sr allows patients a more consistent therapeutic effect throughout the